Cover Image
Market Research Report

Alzheimer's Disease: Pipeline Review, Developer Landscape and Competitive Insights

Published by ROOTS ANALYSIS Product code 808188
Published Content info 220 Pages
Delivery time: 1-2 business days
Price
Back to Top
Alzheimer's Disease: Pipeline Review, Developer Landscape and Competitive Insights
Published: March 31, 2019 Content info: 220 Pages
Description

Example Highlights:

Several investors have realized the lucrative opportunity associated with drug candidates being developed to treat this clinical condition: over USD 2.8 billion has been raised across 180 instances recently.

Overview:

“Alzheimer's disease is both progressive and irreversible, moreover, the cause of the disease is not yet well understood. It is important to generate awareness about the disease among the general population and stay updated with the innovation and research engaged in this domain.” -- Key Opinion Leader and Chief Medical Officer, Large-sized US based Company.

Alzheimer's disease is a neurodegenerative condition characterized by progressive memory loss, cognitive dysfunction anddementia. Currently, it is the most commonly reported neurodegenerative disorder across the world, and the sixth leading cause of death in the US. It was estimated that, in 2018, nearly 5.7 million Americans (considering all age groups) were living with Alzheimer's disease. During the same year, Alzheimer's disease and other dementias were projected to be responsible for a healthcare burden amounting to USD 277 billion, in the US. Considering that only a limited range of diagnosis, treatment and disease management solutions are presently available, this segment of the healthcare industry is presently faced with a pressing need for accurate diagnostic (predictive) tests, and efficient treatment options that have the capability to slow the progression of the condition.

Despite extensive research aimed at comprehending the etiopathogenesis of Alzheimer's disease, only six drugs have been approved since 1996 for treatment. The rate of failure of drugs being developed for treating Alzheimer's disease is alarming (~99.6%) and is even higher than that reported for cancer (~81%). Most of the existing therapeutic options have proven inadequate in arresting the progression of the disease and long term management of associated symptoms. Currently, several stakeholders in the pharmaceutical industry are engaged in efforts to develop various types of disease modifying interventions and drug / therapy candidates that offer symptomatic relief. In fact, multiple initiatives by start-ups are being backed by venture capital and other strategic investors. In the coming years, the market is anticipated to grow at a significant pace as more novel solutions clear clinical evaluation and get commercialized.

Scope of the Report:

The “Alzheimer's Disease Market: Pipeline Review, Developer Landscape and Competitive Insights” report provides an extensive study on the marketed, clinical and preclinical molecules available / being developed for the treatment of Alzheimer's disease. Figure 1.1 summarizes the scope of the report and the specific modules that have been covered in detail in the document.

  • A detailed assessment of the current market landscape, providing information on drug developer(s), phase of development (marketed, clinical and preclinical / discovery stage), type of molecule (small molecule or biologic), type of treatment (disease modifying agents or drugs offering symptomatic relief), target stage of the disease (early, mid and late stages), type of therapy (monotherapy or combination therapy), path to clinic (dedicated, and repositioned / repurposed), mechanism of action, and route of administration of the drugs / therapies being developed for the treatment of the condition.
  • An in-depth analysis of the product pipeline and developer companies, featuring three schematic representations; these include [A] a representation, highlighting the distribution of the marketed and development stage molecules based on the mechanism of action, [B] a 2X2 grid analysis, representing the distribution of drug candidates across type of therapy, path to clinic and stages of development, and [C] a diagrammatic representation of the regional landscape of industry players involved in the development of drugs in this domain, distributed based on the location of their headquarters.
  • An analysis highlighting the key unmet needs across Alzheimer's disease, featuring insights generated through data captured from 5000+ social media posts, 250+ recent scientific publications, 100+ patient blogs and the views of key opinion leaders expressed by both patients and industry experts.
  • A detailed assessment of discontinued drugs / trials, featuring information on the number of discontinuations, year of discontinuation, phase of discontinuation, mechanism of action of the terminated drug, target stage of disease and the reason(s) for discontinuation.
  • A detailed publication analysis of close to 300 articles, highlighting the therapeutic areas of focus within the industry. The analysis also highlights the key trends observed across the publications, including information on popular biological targets being investigated, study type (review article, research article and meta-analysis), year of publication, and the most popular journals (in terms of number of articles published within our dataset) within this domain.
  • An analysis of the partnerships that have been established till 2019 (February), covering R&D collaborations, licensing agreements, mergers and acquisitions, product development and commercialization agreements, manufacturing agreements, and other relevant deals.
  • An analysis of the investments made at various stages of development in companies that are focused in this area, including seed financing, venture capital financing, debt financing, grants, capital raised from IPOs and subsequent offerings.

The research, analysis and insights presented in this report is backed by a deep understanding of insights gathered from secondary sources. The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders in this domain. The report features detailed transcripts of interviews held with the following individuals (in alphabetical order of company name) :

  • Kenneth Moch (President and Chief Executive Officer, Cognition Therapeutics)
  • Ram Bhatt (Chief Executive Officer, Chairman and Founder, ICB International)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Contents:

Chapter 2 provides an executive summary of the insights captured in our research. It offers a high-level view on the likely evolution of the Alzheimer's disease market in the long term.

Chapter 3 provides a brief introduction to Alzheimer's disease, and its associated symptoms. It also features a detailed discussion on the causes of the condition (based on various existing hypotheses), stages of disease progression, factors influencing the onset and progression of the disease, and the different pharmacological and non-pharmacological interventions that are presently indicated for the treatment of this condition. The chapter includes a discussion on the epidemiology of the disease and highlights the diverse initiatives / programs led by the National Institutes of Health (NIH) to support scientific discovery and help in disease management.

Chapter 4 includes information on over 200 molecules that are currently approved / under development for the treatment of Alzheimer's disease. It features a comprehensive analysis of pipeline molecules, highlighting the phase of development (marketed, clinical and preclinical / discovery stage), type of molecule (small molecule or biologic), treatment type (disease modifying agent or drugs offering symptomatic relief), target stage of disease (early, mid or late stage), type of therapy (monotherapy or combination therapy), path to clinics (dedicated, repositioned or repurposed), and mechanism of action and route of administration of the drugs being developed for the treatment of the disease. In addition, the chapter provides information on drug developer(s), highlighting year of their establishment, location of headquarters and employee strength. In addition, it presents certain key insights derived from the study, which includes a representation highlighting the distribution of the marketed and pipeline molecules based on various mechanisms of action. The chapter includes a comprehensive 2X2 grid analysis, representing the distribution of the clinical drug candidates across type of therapy, path to clinic and stage of development. Additionally, the chapter features a regional landscape of developers engaged in this domain, distributed on the basis of the location of their headquarters.

Chapter 5 highlights the key unmet needs associated with the management and treatment of Alzheimer's disease. The chapter provides detailed analysis of the various challenges and areas of concern, which wereidentified from views expressed by patients / experts across different platforms, such as social media posts, recent scientific publications and patient blogs, and the inputs of key opinion leaders at conferences / symposiums. The chapter presents an insightful word cloud analysis, summarizing the opinions expressed across public online portals.

Chapter 6 features a detailed assessment of over 70 discontinued drugs, providing information on the reason(s) for discontinuation, year of discontinuation, mechanism of action of the terminated drugs, phase of discontinuation and the target stage of disease. In addition, the chapter presents over 180 terminated clinical trials highlighting the year of termination and the key geographies where these trials were being conducted.

Chapter 7 provides a detailed analysis of close to 300 research articles related to Alzheimer's disease, published till 2018. The analysis takes into consideration several parameters, such as biological targets being studied, study type (review article, research article, meta-analysis and clinical trials), year of publication, and the most popular journals within this domain.

Chapter 8 features an analysis of the various collaborations and partnerships that have been inked amongst players in this market. We have also discussed different partnership models (including product development and commercialization, R&D agreements, technology / product licensing agreements, other licensing agreements, mergers / acquisitions and clinical trial agreements) that have been established till 2019 (February).

Chapter 9 presents details on various investments received by the start-ups / smaller companies that are engaged in this domain. It also includes an analysis of the funding instances that have taken place in the market, till January 2019, highlighting the growing interest of the venture capital community and other strategic investors within this market.

Chapter 10 provides information on the various non-pharmacological interventions, such as cognitive / emotion-oriented therapies, sensory simulation therapies and other psychological interventions, which aim to delay the loss of mental capability and help the patients retain their identity and functional autonomy. The chapter also presents a list of companies that offer such solutions, describing the devices / products and their mechanisms of action / working principles. In addition, the chapter include a list of novel diagnostic techniques, which claim to be capable of assisting in timely diagnosis.

Chapter 11 summarizes the entire report. It presents a list of key takeaways and our independent opinion on the current market scenario. Further, it captures the evolutionary trends that are likely to determine the future of therapeutic interventions in disease area.

Chapter 12 is a collection of interview transcripts of discussions held with key stakeholders in this market. In this chapter, we have presented the details of interviews held with (in alphabetical order of company name) Kenneth Moch (President and Chief Executive Officer, Cognition Therapeutics)) and Ram Bhatt (Chief Executive Officer, Chairman and Founder, ICB International).

Chapter 13 is an appendix, which provides tabulated data and numbers for all the figures included in the report.

Chapter 14 is an appendix, which contains the list of companies and organizations mentioned in the report.

Table of Contents
Product Code: RA100C05

Table of Contents

1. PREFACE

  • 1.1. Scope of the Report
  • 1.2. Research Methodology
  • 1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

  • 3.1. An Overview of Alzheimer's Disease
    • 3.1.1. Epidemiology
    • 3.1.2. Symptoms of the Disease
    • 3.1.3. Causes of Alzheimer's Disease
    • 3.1.4. Stages of Alzheimer's Disease
  • 3.2. Alzheimer's Disease Research: Government Initiatives and Programs
  • 3.3. Management of Alzheimer's Disease
    • 3.3.1. Interventional Therapies
    • 3.3.2. Non-Interventional Therapies
      • 3.3.2.1. Behavior Management
      • 3.3.2.2. Healthy Living
      • 3.3.2.3. Creating a Safe and a Supportive Environment
  • 3.4. Future Perspectives

4. PIPELINE REVIEW: MARKETED AND CLINICAL DRUGS

  • 4.1. Chapter Overview
  • 4.2. Alzheimer's Disease Therapy: Marketed and Development Pipeline
  • 4.3. Alzheimer's Disease Therapy: Pipeline Analysis
    • 4.3.1. Analysis by Phase of Development
    • 4.3.2. Analysis by Type of Molecule
    • 4.3.3. Analysis by Target Stage of Disease
    • 4.3.4. Analysis by Type of Treatment
    • 4.3.5. Analysis by Mechanism of Action
    • 4.3.6. Analysis by Route of Administration
    • 4.3.7. Analysis by Dosing Frequency
    • 4.3.8. Analysis by Type of Therapy
    • 4.3.9. Analysis by Path to Clinic
    • 4.3.10. Grid Analysis: Distribution by Type of Therapy, Phase of Development and Path to Clinic
  • 4.4. Alzheimer's Disease Therapy: List of Drug Developers
    • 4.4.1. Analysis by Year of Establishment
    • 4.4.2. Analysis by Company Size and Geographical Location
    • 4.4.3. Leading Developers
    • 4.4.4. Grid Analysis: Distribution by Location, Size of Industry Players and Mechanism of Action of Pipeline Drugs
    • 4.4.5. Analysis by Geography

5. ALZHEIMER'S DISEASE: UNMET NEEDS ANALYSIS

  • 5.1. Chapter Overview
  • 5.2. Unmet Needs Associated with Alzheimer's Disease
    • 5.2.1. Analysis of Data from Patient Blogs
      • 5.2.1.1. Methodology
      • 5.2.1.2. Key Insights
    • 5.2.2. Analysis of Data from Published Literature
      • 5.2.2.1. Methodology
      • 5.2.2.2. Key Insights
    • 5.2.3. Analysis of Data from Social Media Platforms
      • 5.2.3.1. Methodology
      • 5.2.3.2. Key Insights
    • 5.2.4. Expert Opinions
      • 5.2.4.1. Rudy Tanzi, Professor of Neurology, Harvard University
      • 5.2.4.2. Samuel Cohen, CEO and Co-Founder, Wren Therapeutics
      • 5.2.4.3. Brandon Brock, Chiropractic Neurologist / Staff Clinician, Cerebrum Health Centers
      • 5.2.4.4. Ronald C Petersen, Director, Mayo Clinic Alzheimer's Disease Research Center and the Mayo Clinic Study of Aging
      • 5.2.4.5. Neal Barnard, Founding President, The Physicians Committee for Responsible Medicine
      • 5.2.4.6. Peter V Rabins, Proffesor, Johns Hopkins University School of Medicines
      • 5.2.4.7. Joe Dispenza, International Lecturer / Professor, Quantum University
      • 5.2.4.8. Freda Lewis-Hall, Chief Medical Officer, Pfizer
      • 5.2.4.9. Dheeraj Roy, Professor, The Broad Institute of MIT and Harvard
      • 5.2.4.10. Joseph Jebelli, Neuroscientist and Author
    • 5.2.5. Summary of Key Unmet Needs associated with Alzheimer's Disease

6. CASE STUDY: TERMINATED DRUGS

  • 6.1. Chapter Overview
  • 6.2. Alzheimer's Disease Therapy: List of Terminated Drugs
    • 6.2.1. Distribution of Drugs by Year of Discontinuation
    • 6.2.2. Distribution by Phase of Discontinuation
    • 6.2.3. Distribution by Mechanism of Action
    • 6.2.4. Distribution of Terminated Drugs by Type of Indication
    • 6.2.5. Distribution by Reason for Termination
    • 6.2.6. Distribution by Affiliated Stakeholders
  • 6.3. Alzheimer's Disease: List of Terminated Clinical Trials
    • 6.3.1. Distribution of Study Start Year and Year of Termination of Clinical Trials
    • 6.3.2. Distribution on Trial Region(s)
  • 6.4. Concluding Remarks

7. PUBLICATION ANALYSIS

  • 7.1. Chapter Overview
  • 7.2. Methodology
  • 7.3. Alzheimer's Disease: List of Publications
    • 7.3.1. Analysis by Type of Study
    • 7.3.2. Analysis by Study Objective
    • 7.3.3. Analysis by Type of Therapeutic Targets
    • 7.3.4. Key Journals

8. PARTNERSHIP AND COLLABORATIONS

  • 8.1. Chapter Overview
  • 8.2. Partnership Models
  • 8.3. Alzheimer's Disease: List of Partnerships and Collaborations
    • 8.3.1. Analysis by Year of Partnership
    • 8.3.2. Analysis by Type of Partnership
    • 8.3.3. Analysis by Focus Area
    • 8.3.4. Regional Analysis
    • 8.3.5. Most Active Players: Analysis by Number of Partnerships

9. FUNDING AND INVESTMENT ANALYSIS

  • 9.1. Chapter Overview
  • 9.2. Types of Funding
  • 9.3. Funding and Investment Analysis
    • 9.3.1. Analysis by Number of Instances
    • 9.3.2. Analysis by Amount Invested
    • 9.3.3. Analysis by Type of Funding
    • 9.3.4. Analysis by Amount Invested across Different Types of Molecules
    • 9.3.5. Regional Analysis by Amount Invested
    • 9.3.6. Most Active Players
    • 9.3.7. Most Active Investors
  • 9.4. Concluding Remarks

10. NON-PHARMACOLOGICAL INTERVENTIONS AND DIAGNOSTICS

  • 10.1. Chapter Overview
  • 10.2. Non-Pharmacological Interventions for Alzheimer's Disease
    • 10.2.1. Cognition / Emotion-Oriented Interventions
      • 10.2.1.1. Reminiscence Therapy
      • 10.2.1.2. Simulated Presence Therapy
    • 10.2.2. Sensory Stimulation-based Interventions
      • 10.2.2.1. Virtual Reality
      • 10.2.2.2. Music Therapy
      • 10.2.2.3. Light Therapy
      • 10.2.2.4. Aromatherapy
      • 10.2.2.5. Reflexology
    • 10.2.3. Other Psychosocial Interventions
      • 10.2.3.1. Animal-Assisted Therapy
  • 10.3. Alzheimer's Disease Therapy: List of Companies Offering Non-Pharmacological Interventions and Diagnostic Tests

11. ALZHEIMER'S DISEASE THERAPY: CONCLUDING REMARKS

12. EXECUTIVE INSIGHTS

  • 12.1. Chapter Overview
  • 12.2. Cognition Therapeutics
    • 12.2.1. Company Snapshot
    • 12.2.2. Interview Transcript: Kenneth Moch, President and Chief Executive Officer
  • 12.3. ICB International
    • 12.3.1. Company Snapshot
    • 12.3.2. Interview Transcript: Ram Bhatt, Chief Executive Officer, Chairman and Founder

13. APPENDIX 1: TABULATED DATA

14. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List of Figures

  • Figure 10.1: Alzheimer's Disease: Non-Pharmacological Interventions
  • Figure 10.2: Alzheimer's Disease: Different Forms of Music Therapy
  • Figure 3.1: Global Statistics of Dementia: 2015 and 2030 (USD Million)
  • Figure 3.2: Alzheimer's Disease: Signs and Symptoms
  • Figure 3.3: Alzheimer's Disease: Normal Brain versus Diseased Brain
  • Figure 3.4: Alzheimer's Disease: Stages of Disease Progression
  • Figure 3.5: Alzheimer's Disease: Natural Remedies for Disease Management
  • Figure 3.6: Alzheimer's Disease: Important Steps toward Creating a Supportive Environment
  • Figure 4.1: Alzheimer's Disease Therapy: Distribution by Phase of Development
  • Figure 4.10: Grid Analysis: Distribution of Pipeline Therapies by Phase of Development, Type of Therapy and Path to Clinic
  • Figure 4.11: Alzheimer's Disease: Distribution by Year of Establishment of Developer
  • Figure 4.12: Alzheimer's Disease: Distribution by Size and Location of Developer
  • Figure 4.13: Pipeline Analysis: Geographical Landscape
  • Figure 4.14: Grid Analysis: Distribution by Location, Size of Industry Players and Mechanism of Action of Pipeline Drugs
  • Figure 4.2: Alzheimer's Disease Therapy: Distribution by Type of Molecule
  • Figure 4.3:: Alzheimer's Disease Therapy: Distribution by Target Stage of Disease
  • Figure 4.4: Alzheimer's Disease Therapy: Distribution by Type of Treatment
  • Figure 4.5: Alzheimer's Disease Therapy: Distribution by Mechanism of Action
  • Figure 4.6: Alzheimer's Disease Therapy: Distribution by Route of Administration
  • Figure 4.7: Alzheimer's Disease Therapy: Distribution by Dosing Frequency
  • Figure 4.8: Alzheimer's Disease Therapy: Distribution by Type of Therapy
  • Figure 4.9: Alzheimer's Disease Therapy: Distribution by Path to Clinic
  • Figure 5.1: Unmet Needs Analysis: Overview of Methodology
  • Figure 5.2: Unmet Needs in Alzheimer's Disease: Word Cloud Analysis of Patient Blog Data
  • Figure 5.3: Unmet Needs in Alzheimer's Disease: Needs Highlighted across Published Literature
  • Figure 5.4: Unmet Needs in Alzheimer's Disease: Word Cloud Analysis of Data from Social Media
  • Figure 5.5: Unmet Needs in Alzheimer's Disease: Summary
  • Figure 6.1: Terminated Drugs: Cumulative Distribution of Drugs by Year of Discontinuation
  • Figure 6.10: Terminated Drugs: Regional Distribution of Failed Clinical Trials
  • Figure 6.11: Terminated Drugs: Precaution for Evaluating New Clinical Trials
  • Figure 6.12: Bubble Analysis: Distribution by Year of Termination, Reason of Termination and Phase of Development
  • Figure 6.2: Terminated Drugs: Distribution by Phase of Discontinuation
  • Figure 6.3: Terminated Drugs: Distribution by Mechanism of Action
  • Figure 6.4: Terminated Drugs: Distribution of Terminated Drugs by Type of Indication
  • Figure 6.5: Terminated Drugs: Distribution by Affiliated Stakeholders
  • Figure 6.6: Terminated Drugs: Distribution by Reason for Termination
  • Figure 6.7: Bubble Analysis: Relative Distribution by Reason of Termination and Phase of Development
  • Figure 6.8: Terminated Drugs: Word Cloud of Reason of Termination
  • Figure 6.9: Terminated Drugs: Distribution by Study Start Year and Year of Termination of the Clinical Trials for Alzheimer's Disease
  • Figure 7.1: Publications: Year-wise Trend, 2010-2018
  • Figure 7.2: Publications: Distribution by Type of Study
  • Figure 7.3: Publications: Distribution by Study Objective
  • Figure 7.4: Publications: Word Cloud on Therapeutic Targets
  • Figure 7.5: Publications: Most Popular Journals
  • Figure 8.1: Partnerships and Collaborations: Cumulative Trend by Year, 2012-2018
  • Figure 8.2: Partnerships and Collaborations: Distribution by Type of Partnership
  • Figure 8.3: Partnerships and Collaborations: Distribution by Year of Partnership and Therapeutic Area
  • Figure 8.4: Partnerships and Collaborations: Distribution by Type of Partnership, 2012-2015 and Post 2015
  • Figure 8.5: Partnerships and Collaborations: Activity of Big Pharmaceutical Companies
  • Figure 8.6: Partnerships and Collaborations: Regional Distribution
  • Figure 8.7: Partnerships and Collaborations: Intercontinental and Intracontinental Distribution
  • Figure 8.8: Partnership and Collaborations: Distribution by Focus Area
  • Figure 8.9: Partnerships and Collaborations: Most Active Players
  • Figure 9.1: Funding and Investments: Cumulative Number of Instances, 2013-2019
  • Figure 9.10: Funding and Investments: Most Active Players (by Amount Received)
  • Figure 9.11: Funding and Investments: Most Active Investors
  • Figure 9.12: Funding and Investments Summary
  • Figure 9.2: Funding and Investments: Distribution by Type of Funding, 2013-2019
  • Figure 9.3: Funding and Investments: Distribution by Type of Funding and Year, 2013-2019
  • Figure 9.4: Funding and Investments: Cumulative Amount Invested, 2013-2019 (USD Million)
  • Figure 9.5: Funding and Investments: Distribution of Total Amount Invested by Type of Funding, 2013-2019 (USD Million)
  • Figure 9.6: Funding and Investments: Summary of Investments, 2013-2019 (USD Million)
  • Figure 9.7: Funding and Investments: Most Funded Molecules
  • Figure 9.8: Funding and Investments: Popular Mechanisms of Action (by Amount Invested)
  • Figure 9.9: Funding and Investments: Distribution by Geography

List of Tables

  • Table 4.1: Alzheimer's Disease Therapy: Marketed and Development Pipeline
  • Table 4.2: Alzheimer's Disease Therapy: Information on Type of Therapy and Path to Clinic
  • Table 4.3: Alzheimer's Disease Therapy: Developer Overview
  • Table 4.4: Alzheimer's Disease Therapy: Initiatives by Large Pharma Players
  • Table 6.1: Alzheimer's Disease: Pipeline of Terminated Drugs
  • Table 6.2: Alzheimer's Disease: List of Terminated Clinical Trials
  • Table 7.1: Alzheimer's Disease: List of Publications, 2017-2018
  • Table 8.1: Alzheimer's Disease: Partnerships and Collaborations, 2013-2019
  • Table 9.1: Alzheimer's Disease Market: Funding and Investments, 2013-2019
  • Table 9.2: Funding and Investment Analysis: Summary of Investments
  • Table 10.1: Alzheimer's Disease: List of Companies Providing Non-Pharmacological Interventions and Diagnostic Tests
  • Table 11.1: Alzheimer's Disease: Concluding Remarks
  • Table 12.1: Cognition Therapeutics: Key Highlights
  • Table 12.2: ICB International: Key Highlights
  • Table 13.1: Alzheimer's Disease Therapy: Distribution by Phase of Development
  • Table 13.2: Alzheimer's Disease Therapy: Distribution by Type of Molecule
  • Table 13.3: Alzheimer's Disease Therapy: Distribution by Target Stage of Disease
  • Table 13.4: Alzheimer's Disease Therapy: Distribution by Type of Treatment
  • Table 13.5: Alzheimer's Disease Therapy: Distribution by Type of Mechanism of Action
  • Table 13.6: Alzheimer's Disease Therapy: Distribution by Route of Administration
  • Table 13.7: Alzheimer's Disease Therapy: Distribution by Dosing Frequency
  • Table 13.8: Alzheimer's Disease Therapy: Distribution by Type of Therapy
  • Table 13.9: Alzheimer's Disease Therapy: Distribution by Path to Clinic
  • Table 13.10: Drug Developers for Alzheimer's Disease: Distribution by Year of Establishment of Developer
  • Table 13.11: Alzheimer's Disease Therapy: Distribution by Size and Location of Developer
  • Table 13.12: Alzheimer's Disease Therapy: Leading Players
  • Table 13.13: Alzheimer's Disease Therapy: Comparison of Top Players
  • Table 13.14: Unmet Needs in Alzheimer's Disease: Needs Highlighted across Published Literature
  • Table 13.15: Terminated Drugs: Cumulative Distribution of Drugs by Year of Discontinuation
  • Table 13.16: Terminated Drugs: Distribution by Phase of Discontinuation
  • Table 13.17: Terminated Drugs: Distribution by Mechanism of Action
  • Table 13.18: Terminated Drugs: Distribution of Terminated Drugs by Type of Indication
  • Table 13.19: Terminated Drugs: Distribution by Affiliated Stakeholders
  • Table 13.20: Terminated Drugs: Distribution by Reason for Termination
  • Table 13.21: Terminated Drugs: Distribution by Study Start Year and Year of Termination of the Clinical Trials for Alzheimer's Disease
  • Table 13.22: Publications: Year-wise Trend, 2010-2018
  • Table 13.23: Publications: Distribution by Type of Study
  • Table 13.24: Publications: Distribution by Study Objective
  • Table 13.25: Publications: Most Popular Journals
  • Table 13.26: Partnerships and Collaborations: Cumulative Trend by Year, 2012-2018
  • Table 13.27: Partnerships and Collaborations: Distribution by Type of Partnership
  • Table 13.28: Partnerships and Collaborations: Distribution by Year of Partnership and Therapeutic Area
  • Table 13.29: Partnerships and Collaborations: Distribution by Type of Partnership, 2012-2015 and Post 2015
  • Table 13.30: Partnerships and Collaborations: Activity of Big Pharmaceutical Companies
  • Table:13.31: Partnership and Collaborations: Distribution by Focus Area
  • Table 13.32: Partnerships and Collaborations: Most Active Players
  • Table 13.33: Funding and Investments: Cumulative Number of Instances, 2013-2019
  • Table 13.34: Funding and Investments: Distribution by Type of Funding, 2013-2019
  • Table 13.35: Funding and Investments: Distribution by Type of Funding and Year, 2013-2019
  • Table 13.36: Funding and Investments: Cumulative Amount Invested, 2013-2019 USD Million)
  • Table 13.37: Funding and Investments: Distribution of Total Amount Invested by Type of Funding, 2013-2019 (USD million)
  • Table 13.38: Funding and Investments: Summary of Investments
  • Table 13.39: Funding and Investments: Most Funded Molecules
  • Table 13.40: Funding and Investments: Popular Mechanisms of Action (by Amount Invested)
  • Table 13.41: Funding and Investments: Most Active Players (by Amount Received)
  • Table 13.42: Funding and Investments: Most Active Investors
  • Table 13.43: Funding and Investments Summary

Listed Companies:

The following companies and organizations have been mentioned in the report:

  • 23andMe
  • 3M
  • AB Science
  • Abbott
  • AbbVie
  • Abcam
  • AC Immune
  • ACADIA Pharmaceuticals
  • Accera
  • Access Industries
  • Acelot
  • Actinogen Medical
  • Acumen Pharmaceuticals
  • ADmit Therapeutics
  • Affilogic
  • AFFiRiS
  • Agency for Innovation and Entrepreneurship
  • AgeneBio
  • Alector
  • Alectos Therapeutics
  • Alkahest
  • Allergan
  • Alliance Global Partners
  • Allinky Biopharma
  • Allon Therapeutics
  • American Life Science Pharmaceuticals
  • Altoida
  • Alzheimer's Drug Discovery Foundation
  • Alzheimer's Association
  • Alzheimer's Disease Cooperative Study
  • Alzheimer's Drug Discovery Foundation
  • Alzheon
  • Alzinova
  • AlzProtect
  • Amylyx Pharmaceuticals
  • Anavex Life Sciences
  • Andera Partners
  • Aphios
  • APRINOIA Therapeutics
  • Aquinnah Pharmaceuticals
  • ARCH Venture Partners
  • Archer Pharmaceuticals
  • ArmaGen
  • ARMGO Pharma
  • Arrien Pharmaceuticals
  • Asceneuron
  • Astellas Pharma
  • AstraZeneca
  • Atlas Venture
  • Ausio Pharmaceuticals
  • Autifony Therapeutics
  • Avanir Pharmaceuticals
  • Avid Bioservices
  • Avineuro Pharmaceuticals
  • Axon Neuroscience
  • Axovant Sciences
  • Axsome Therapeutics
  • AZTherapies
  • Baillie Gifford
  • Bain Capital Life Sciences
  • Banner Alzheimer's Institute
  • Baxalta
  • BELLUS Health
  • BioArctic
  • Biogen
  • Biohaven Pharmaceuticals
  • Biomar Microbial Technologies
  • Biomedical Catalyst
  • Bionomics
  • BioPharmaceuticals Australia
  • Bios Memory SPV1
  • Biotechnology Value Fund
  • Biotherapix
  • BlueTree Allied Angels
  • Boehringer Ingelheim
  • BOLD Capital Partners
  • Bpifrance
  • Brain Biomarker Solutions
  • Brain Canada
  • Brain Chemistry Laboratories
  • BrainsWay
  • Brainvectis
  • Breakout Labs
  • Bristol-Myers Squibb
  • Burke Neurological Institute
  • C4 Therapeutics
  • Camargo Pharmaceutical Services
  • Canadian Institutes of Health Research
  • CarThera
  • CDC Entreprises
  • Celgene
  • Cenna Biosciences
  • Centrose
  • Cerebain Biotech
  • Cerecin
  • CereSpir
  • Cerveau Technologies
  • CHA Biotech
  • Chang Gung Memorial Hospital
  • Changchun Huayang High-tech
  • Chaperone Therapeutics
  • Charsire Biotechnology
  • Chelsea Therapeutics
  • Clarus Ventures
  • Clera
  • Cleveland Clinic
  • Clinical Research Services Turku
  • Cogentis Therapeutics
  • Cognition Therapeutics
  • Cognoptix
  • Cognosci
  • Columbia University
  • Congenia
  • CoPlex Therapeutics
  • Corcept Therapeutics
  • Corium International
  • Cortexyme
  • Cortice Biosciences
  • Crossbeta Biosciences
  • CuraSen Therapeutics
  • Cypralis
  • DAE HWA Pharmaceutical
  • Daewoong Pharmaceutical
  • Dartmouth-Hitchcock Medical Center
  • Dawson James Securities
  • DCI Partners
  • Deerfield Management
  • Delenex Therapeutics
  • Dementia Discovery Fund
  • Denali Therapeutics
  • DiamiR
  • Dicerna Pharmaceuticals
  • Digna Biotech
  • Dolby Family Ventures
  • Douglas Mental Health University Institute
  • Dthera Sciences
  • DuChemBio
  • Dundee Corporation
  • Edunn Biotechnology
  • EIP Pharma
  • Eisai
  • Elan
  • Eli Lilly and Company
  • Emergent BioSolutions
  • Emory University
  • Epigen Biosciences
  • EPIX Pharmaceuticals
  • E-Scape Bio
  • Essex Bio-Technology
  • Evotec
  • F-Prime Capital
  • Finovam
  • Forbion
  • Forrest Capital
  • Fortuna Fix
  • FORUM Pharmaceuticals
  • Fountain Healthcare Partners
  • FUJIFILM Holdings America
  • FUJIFILM Toyama Chemical
  • Fujirebio
  • FundaciÓ ACE
  • FutureNeuro
  • GCA Therapeutics
  • GemVax & Kael
  • Genentech
  • Genervon Biopharmaceuticals
  • Genzyme
  • Georgetown University
  • German Center for Neurodegenerative Diseases
  • GigaGen
  • Gismo Therapeutics
  • GlaxoSmithKline
  • GliaCure
  • GliaPharm
  • GNT Pharma
  • Google
  • Grand Angels
  • Grifols
  • Gurnet Point Capital
  • Lundbeck
  • Harvard Medical School
  • Heptares Therapeutics
  • Herantis Pharma
  • High Point Pharmaceuticals
  • HOPU Investment Management
  • HSRx Biopharmaceutical
  • Humana
  • Santa Lucia Foundation
  • IBM Watson Health
  • IlDong Pharmaceutical
  • ImmunoBrain Checkpoint
  • Impel NeuroPharma
  • Imperial College London
  • Inflazome
  • Innovative California Biosciences International
  • INSIGHTEC
  • IntelGenx
  • Intellect Neurosciences
  • Intra-Cellular Therapies
  • INVENT Pharmaceuticals
  • Io Therapeutics
  • Ionis Pharmaceuticals
  • Ipsen
  • Janssen Pharmaceuticals
  • Jiangsu Sheneryang High-tech
  • Johns Hopkins University
  • JSW Lifesciences
  • Jupiter Orphan Therapeutics
  • KalGene Pharmaceuticals
  • Kareus Therapeutics
  • Karuna Pharmaceuticals
  • Keio University
  • Keio University School of Medicine
  • K-PAX Pharmaceuticals
  • KTB Network
  • Kyowa Hakko Kirin
  • La Caixa Banking Foundation
  • New Leaf Venture Partners
  • Leerink Partners
  • Lincoln Park Capital
  • Lipopharma
  • Longeveron
  • Longitude Capital
  • Lonza
  • Luminex
  • Lumira Capital
  • Lyndra Therapeutics
  • M3 Biotechnology
  • Maryland Technology Development
  • Massachusetts Institute of Technology
  • McGill University
  • McLean Hospital
  • MedDay Pharmaceuticals
  • Medesis Pharma
  • Medical Research Council Technology
  • Medipost
  • Mediti Pharma
  • Memory Pharmaceuticals
  • Merck
  • Merieux Developpement
  • Merz Pharmaceuticals
  • Metabolic Solutions Development
  • Mission Therapeutics
  • Mithridion
  • Mitsubishi Tanabe Pharma
  • Mylan
  • Myrexis
  • NasVax
  • National Institute on Aging
  • National Institutes of Health
  • National Research Council of Canada
  • National University Hospital
  • Nature Cell
  • Neocodex
  • Neuralstem
  • Neuraltus Pharmaceuticals
  • Neuraly
  • Neurim Pharmaceuticals
  • Neurocentria
  • Neurodon
  • Neurogeneration
  • NeuroGenetic Pharmaceuticals
  • Neuron Bio
  • Neuronascent
  • Neuronix
  • NeurOp
  • Neurotech Pharmaceuticals
  • Neurotez
  • Neurotrack
  • Neurotrope Bioscience
  • NeuroVentures Capital
  • Neurovision Medical Products
  • New World Laboratories
  • New York State Psychiatric Institute
  • Nichi-Iko Pharmaceuticals
  • Niigata University
  • Nikon
  • Nord France Amorçage
  • Novartis
  • Novartis Venture Fund
  • Novo Nordisk
  • Octapharma
  • Oligomerix
  • Oncovision
  • Optina Diagnostics
  • OrbiMed
  • OrbiMed Advisors
  • Orion Pharma
  • Oryzon
  • Otsuka Pharmaceutical
  • Oxford Drug Discovery Institute
  • P2D Bioscience
  • Pain Therapeutics
  • Panorama Research
  • PAREXEL International
  • Pfizer
  • Pfizer Venture Investments
  • PharmaNeuroBoost NV
  • PharmatrophiX
  • Phenomenome Discoveries
  • PLSG Accelerator Fund
  • PMV
  • Polaris Partners
  • Proactive Investor
  • Probiodrug
  • Proclara Biosciences
  • Progenra
  • Project ALS
  • ProMIS Neurosciences
  • Proteome Sciences
  • Proteostasis Therapeutics
  • ProteoTech
  • QMENTA
  • QR Pharma
  • Regenera Pharma
  • RemeGenix
  • reMYND
  • Rentschler Biopharma
  • Revalesio
  • Reviva Pharmaceuticals
  • Robin Hood Ventures
  • Roche
  • The Rockefeller University
  • Rodin Therapeutics
  • San Diego Regenerative Medicine Institute
  • Sanford Burnham Prebys Medical Discovery Institute
  • Sangamo Therapeutics
  • Sanofi
  • Science Exchange
  • Senexis
  • Servier
  • Shanghai Green valley Pharmaceutical
  • Shanghai Mental Health Center
  • Shionogi
  • Shire
  • Signum Biosciences
  • Sinphar Pharmaceutical
  • Skyhawk Therapeutics
  • Solvay Pharmaceuticals
  • Sosei Heptares
  • SpringWorks Therapeutics
  • Stanford University
  • Stanley Family Foundation
  • Stemedica Cell Technologies
  • Sunnybrook Health Sciences Centre
  • Suven Life Sciences
  • Sysmex
  • T3D Therapeutics
  • Takeda Pharmaceutical
  • TauRx Therapeutics
  • Teijin Pharma
  • Tetra Discovery Partners
  • Teva Pharmaceutical
  • The Alzheimer's Drug Discovery Foundation
  • The Stanley Center for Psychiatric Research at Broad Institute
  • The Dana Foundation
  • The Foundation for Technological Innovation
  • The University of British Columbia
  • Tianjin Pharmaceutical Holdings
  • Tonix Pharmaceuticals
  • TorreyPines Therapeutics
  • Transition Therapeutics
  • TRB Chemedica International
  • Treventis
  • TVM Capital Life Science
  • Umea Institute of Design
  • United Neuroscience
  • University College London
  • University Hospital Bonn
  • University Hospital of Brasília
  • University of Antioquia
  • University of California
  • University of Colorado Denver
  • University of Dundee Drug Discovery Unit
  • University of Dundee
  • University of Gottingen
  • University of Kansas Medical Centre
  • University of Kentucky
  • University of Massachusetts
  • University of Minnesota
  • University of Rochester
  • University of Southern California
  • University of Texas
  • University of Wisconsin
  • Uppsala University
  • VA Office of Research and Development
  • Avalon AI
  • Vanderbilt University
  • Varinel
  • Vertex Pharmaceuticals
  • Vielight
  • Vitae Pharmaceuticals
  • Vivreon Biosciences
  • Voyager Therapeutics
  • vTv Therapeutics
  • Wake Forest School of Medicine
  • Wake Forest University
  • Wave Life Sciences
  • Wellcome Trust
  • Weston Brain Institute
  • Wilmar International
  • Winterlight Labs
  • WuXi Biologics
  • Xcelthera
  • XoNovo
  • Yale University
  • Ybrain
  • Zeltia
Back to Top